课题基金 / 基金详情

Gene therapy and enzyme replacement for Batten disease

Gene therapy and enzyme replacement for Batten disease
巴顿病的基因疗法和酶替代
批准号:
7111366
负责人:
MICHAEL CHANG
金额:
$2.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-03-16 至 2008-03-15

项目摘要

项目成果

MICHAEL CHANG的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):这项提案的重点是影响D中枢神经系统的溶酶体储存疾病的基因治疗方法。使用晚期婴儿神经元型蜡样脂褐素沉积症(LINCL/Batten病)作为D模型疾病,我建议测试关于将基因传递到小鼠疾病D模型的中枢神经系统的假说。我们实验室的最新数据显示,4型腺相关病毒(AAV4)能有效地引导D溶酶体酶在小鼠脑内的广泛分布,这是一个令人兴奋的发现,因为D LINCL患者表现出广泛的中枢神经系统病理。这里将测试AAV4在LINCL小鼠D模型中直接基因转移的能力。此外,我建议开发一种四环素调节的病毒载体,因为临床应用基因转移可能需要调节表达,以将免疫反应C或其他不良反应降至最低。一个受调控的载体也将使我能够解决D停止酶表达后的益处持续时间。
英文摘要
DESCRIPTION (provided by applicant): This proposal is focused on gene therapy approaches for lysosomal storage diseases affecting the D central nervous system. Using late infantile neuronal ceroid lipofuscinosis (LINCL / Batten Disease) as a D model disease, I propose to test hypotheses regarding delivery of a gene to the CNS of a murine disease D model. Recent data from our lab shows that adeno-associated virus type 4 (AAV4) is effective in directing D widespread distribution of a lysosomal enzyme in the murine brain, which is an exciting finding given that D LINCL patients exhibit widespread CNS pathology. The ability of AAV4 to direct gene transfer in a mouse D model of LINCL will be tested here. In addition, I propose to develop a tetracycline-regulated viral vector as I clinical applications of gene transfer will likely require regulated expression to minimize immune responses C or other adverse effects. A regulated vector will also allow me to address the duration of benefits after D cessation of enzyme expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene therapy and enzyme replacement for Batten disease
  • 批准号:
    7216898
  • 项目类别:
  • 资助金额:
    $2.38万
  • 财政年份:
    2006
  • 负责人:
    MICHAEL CHANG
  • 依托单位:
海外基金